Hunter focuses his health law practice primarily on Drug Enforcement Administration (DEA) matters, including litigation and regulatory compliance under the Controlled Substances Act (CSA) for clients in the pharmaceutical industry. Specifically, he specializes in areas of anti-diversion practices and suspicious order monitoring for manufacturers and distributors. He also counsels pharmacies and other practitioners on their policies and procedures for the handling of controlled substances. Relatedly, he represents clients through DEA (and other regulatory bodies) investigations associated with concerns of either diversion, record-keeping violations, or other regulatory matters.

Hunter's representative experience includes:

• Advising large wholesale drug distributors on DEA compliance, suspicious order monitoring (SOM) policies and procedures, customer risk assessment regarding historical purchasing patterns, and other DEA-related matters;


• Representing wholesale drug distributors in national opioid multidistrict litigation (MDL); and


• Defending prescribers and dispensers investigated by the DEA, states' attorneys general, and boards of pharmacy.